Evidence map›Paper›PMID 25239949›Full record

ReviewArchives of disease in childhood2015

Sickle cell disease: a neglected chronic disease of increasing global health importance.

Subarna Chakravorty, Thomas N Williams

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Archives of disease in childhood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05253781 (Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy), which is not on this map. Cited by 93 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 10 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05253781 phase3completednot on this mapstarted 2020, after this paper: background citation

Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial

TypeinterventionalSponsorUniversity of Lagos, NigeriaRan2020 to 2024Enrolled476ConditionsIntrauterine Growth Restriction, Preeclampsia, Sickle Cell Disease, Pregnancy ComplicationsArmsLow-dose aspirin, Placebo
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 10 syntheses or guidelines pooled it, 227 citations in OpenAlex.

  1. Hydroxyurea (hydroxycarbamide) for sickle cell disease.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Pooled it
  3. Preoperative blood transfusions for sickle cell disease.The Cochrane database of systematic reviews · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Hydroxyurea (hydroxycarbamide) for sickle cell disease.The Cochrane database of systematic reviews · 2017
    Pooled it
  9. Pooled it
  10. Preoperative blood transfusions for sickle cell disease.The Cochrane database of systematic reviews · 2016
    Pooled it
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Prevalence, risk factors, and demographic insights of sickle cell hepatopathy in Omani adolescents and adults: A retrospective analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025
    Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Subarna ChakravortyDepartment of Medicine, Imperial College, London, UK.
Thomas N WilliamsDepartment of Medicine, Imperial College, London, UK KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Imperial College London · GB

Funding

Wellcome Trust 091758Wellcome Trust 092654
6 · The paper itself

Abstract

Sickle cell disease (SCD) is a single gene disorder causing a debilitating systemic syndrome characterised by chronic anaemia, acute painful episodes, organ infarction and chronic organ damage and by a significant reduction in life expectancy. The origin of SCD lies in the malarial regions of the tropics where carriers are protected against death from malaria and hence enjoy an evolutionary advantage. More recently, population migration has meant that SCD now has a worldwide distribution and that a substantial number of children are born with the condition in higher-income areas, including large parts of Europe and North and South America. Newborn screening, systematic clinical follow-up and prevention of sepsis and organ damage have led to an increased life expectancy among people with SCD in many such countries; however, in resource-limited settings where the majority continue to be born, most affected children continue to die in early childhood, usually undiagnosed, due to the lack of effective programmes for its early detection and treatment. As new therapies emerge, potentially leading to disease amelioration or cure, it is of paramount importance that the significant burden of SCD in resource-poor countries is properly recognised.

Indexed as

Anemia, Sickle CellChildChild, PreschoolChronic DiseaseGlobal HealthHumansInfant, NewbornNeglected DiseasesNeonatal ScreeningHaematologysickle cell disease

Identifiers

PMID25239949
PMCPMC4285890
OpenAlexW2137367581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.